PL1692281T3 - Identyfikacja mutacji JAK2 w czerwienicy prawdziwej - Google Patents

Identyfikacja mutacji JAK2 w czerwienicy prawdziwej

Info

Publication number
PL1692281T3
PL1692281T3 PL05815749T PL05815749T PL1692281T3 PL 1692281 T3 PL1692281 T3 PL 1692281T3 PL 05815749 T PL05815749 T PL 05815749T PL 05815749 T PL05815749 T PL 05815749T PL 1692281 T3 PL1692281 T3 PL 1692281T3
Authority
PL
Poland
Prior art keywords
mutation
identification
polycythemia vera
jak2
jak2 mutation
Prior art date
Application number
PL05815749T
Other languages
English (en)
Polish (pl)
Inventor
William Vainchenker
Valérie Ugo
Chloé James
Couedic Jean-Pierre Le
Nicole Casadevall
Original Assignee
Hopitaux Paris Assist Publique
Inst Nat Sante Rech Med
Roussy Inst Gustave
Univ Versailles Saint Quentin En Yvelines
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34953071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1692281(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hopitaux Paris Assist Publique, Inst Nat Sante Rech Med, Roussy Inst Gustave, Univ Versailles Saint Quentin En Yvelines, Univ Paris Sud filed Critical Hopitaux Paris Assist Publique
Publication of PL1692281T3 publication Critical patent/PL1692281T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
PL05815749T 2004-10-27 2005-10-26 Identyfikacja mutacji JAK2 w czerwienicy prawdziwej PL1692281T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411480A FR2877013A1 (fr) 2004-10-27 2004-10-27 Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
PCT/EP2005/055586 WO2006045827A1 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez
EP05815749A EP1692281B8 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez

Publications (1)

Publication Number Publication Date
PL1692281T3 true PL1692281T3 (pl) 2008-06-30

Family

ID=34953071

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05815749T PL1692281T3 (pl) 2004-10-27 2005-10-26 Identyfikacja mutacji JAK2 w czerwienicy prawdziwej

Country Status (20)

Country Link
US (9) US7781199B2 (https=)
EP (2) EP1895000A1 (https=)
JP (3) JP5090171B2 (https=)
KR (1) KR101203003B1 (https=)
CN (1) CN101072870B (https=)
AT (1) ATE382082T1 (https=)
AU (1) AU2005298636B2 (https=)
BR (1) BRPI0517398B8 (https=)
CA (3) CA2647086C (https=)
DE (1) DE602005004008T2 (https=)
DK (1) DK1692281T3 (https=)
ES (1) ES2296229T3 (https=)
FR (1) FR2877013A1 (https=)
IL (1) IL182761A0 (https=)
MX (1) MX2007005174A (https=)
PL (1) PL1692281T3 (https=)
PT (1) PT1692281E (https=)
SI (1) SI1692281T1 (https=)
WO (1) WO2006045827A1 (https=)
ZA (1) ZA200703433B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
CN100497657C (zh) * 2006-09-27 2009-06-10 北京大学人民医院 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) * 2006-11-15 2008-06-26 Eragen Biosciences, Inc. Methods and kits for detecting jak2 nucleic acid
US8367078B2 (en) * 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
US20100068713A1 (en) * 2007-07-13 2010-03-18 Arkray, Inc. Probe for detecting mutation in jak2 gene and use thereof
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
ATE554189T1 (de) 2009-07-10 2012-05-15 Biotrin Internat Ltd Hochsensibles schnelles isothermisches verfahren zur detektion von punktmutationen und snps
WO2011067373A1 (fr) * 2009-12-04 2011-06-09 Assistance Publique - Hopitaux De Paris Methode de detection d'une polyglobulie chez un chien
AU2011214254B2 (en) * 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
US20120021413A1 (en) * 2010-04-30 2012-01-26 Arkray, Inc. Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
US10174364B2 (en) * 2010-07-16 2019-01-08 Stichting Vu-Vumc Method of analysing a blood sample of a subject for the presence of a disease marker
US10174365B2 (en) 2011-03-18 2019-01-08 Stichting Vu-Vumc Method of analysing a blood sample of a subject for the presence of a disease marker
JP2013017395A (ja) * 2011-07-07 2013-01-31 Toyobo Co Ltd 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) 2011-09-30 2011-11-16 Epistem Ltd Mutational analysis of JAK2
CN103243153B (zh) * 2012-02-10 2014-11-05 复旦大学附属华山医院 Jak2 v617f突变的检测应用
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
EP2917341B1 (en) 2012-11-08 2017-09-27 Centre National de la Recherche Scientifique (CNRS) New phosphodeoxyribosyltransferase mutant enzymes and uses thereof
WO2014074847A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
EP2997436B1 (en) 2013-05-16 2022-02-16 Mobelisk Group, LLC Modular tablet case
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US20180318303A1 (en) * 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders
MX389138B (es) 2015-04-23 2025-03-20 Quest Diagnostics Invest Inc Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
CN105441573A (zh) * 2016-01-11 2016-03-30 武汉海吉力生物科技有限公司 用于检测人类jak2基因v617f突变的引物、探针及试剂盒
EP3468585A2 (en) * 2016-06-10 2019-04-17 IO Biotech APS Calr and jak2 vaccine compositions
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
KR20250074692A (ko) 2018-11-29 2025-05-27 제론 코포레이션 골수이형성 증후군을 치료하는 방법
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
CA2306446A1 (en) 1998-09-25 2000-04-06 Massachusetts Institute Of Technology Methods and products related to genotyping and dna analysis
AU2001251612A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1440287A (zh) * 2000-06-30 2003-09-03 辉瑞大药厂 治疗外周血管疾病、外周神经病和自主神经病的方法
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds
US20050235375A1 (en) * 2001-06-22 2005-10-20 Wenqiong Chen Transcription factors of cereals
US20060240418A1 (en) 2002-05-03 2006-10-26 Diggans James C Canine gene microarrays
JP2005532070A (ja) * 2002-07-03 2005-10-27 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Ｍｄａ−７媒介型アポトーシスの調節因子の同定方法
AU2003278725A1 (en) * 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en) * 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid
US20130007927A1 (en) * 2010-01-22 2013-01-03 Chromatin, Inc. Novel centromeres and methods of using the same

Also Published As

Publication number Publication date
CA2754028A1 (fr) 2006-05-04
WO2006045827A1 (fr) 2006-05-04
US7781199B2 (en) 2010-08-24
US20150051263A2 (en) 2015-02-19
EP1692281A1 (fr) 2006-08-23
MX2007005174A (es) 2007-10-10
EP1692281B8 (fr) 2008-02-13
CN101072870A (zh) 2007-11-14
SI1692281T1 (sl) 2008-04-30
US10563200B2 (en) 2020-02-18
AU2005298636A1 (en) 2006-05-04
KR101203003B1 (ko) 2012-11-21
US20120066776A1 (en) 2012-03-15
US20060288432A1 (en) 2006-12-21
FR2877013A1 (fr) 2006-04-28
IL182761A0 (en) 2007-07-24
BRPI0517398B1 (pt) 2021-03-02
JP5290884B2 (ja) 2013-09-18
HK1094974A1 (zh) 2007-04-20
CN101072870B (zh) 2013-01-30
CA2647086A1 (fr) 2006-05-04
KR20070104338A (ko) 2007-10-25
US20200140863A1 (en) 2020-05-07
CA2647086C (fr) 2012-09-18
DE602005004008D1 (de) 2008-02-07
PT1692281E (pt) 2008-02-06
CA2585062C (fr) 2012-11-20
BRPI0517398A (pt) 2008-10-14
DK1692281T3 (da) 2008-05-13
DE602005004008T2 (de) 2009-02-12
US11162100B2 (en) 2021-11-02
US8852931B2 (en) 2014-10-07
JP2009278982A (ja) 2009-12-03
US20130189683A1 (en) 2013-07-25
US20140249204A1 (en) 2014-09-04
US20090162849A1 (en) 2009-06-25
BRPI0517398B8 (pt) 2021-05-25
ATE382082T1 (de) 2008-01-15
EP1692281B1 (fr) 2007-12-26
JP5090171B2 (ja) 2012-12-05
ZA200703433B (en) 2008-08-27
US7429456B2 (en) 2008-09-30
AU2005298636B2 (en) 2009-11-26
US10364430B2 (en) 2019-07-30
JP6103691B2 (ja) 2017-03-29
JP2013135673A (ja) 2013-07-11
ES2296229T3 (es) 2008-04-16
EP1895000A1 (fr) 2008-03-05
US20220042016A1 (en) 2022-02-10
US8466338B2 (en) 2013-06-18
JP2008517613A (ja) 2008-05-29
CA2585062A1 (fr) 2006-05-04
US20080076135A1 (en) 2008-03-27
US8637235B2 (en) 2014-01-28
US20190323007A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
PL1692281T3 (pl) Identyfikacja mutacji JAK2 w czerwienicy prawdziwej
WO2003012105A3 (en) Vegf isoform
DK1562983T3 (da) Flere varianter af meningokok-protein NMB1870
BRPI0516176A (pt) polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina
ATE454396T1 (de) Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
EA201000327A1 (ru) Белок
EP1739174A4 (en) MUTATED GLUCOSE DEHYDROGENASE
IL170669A0 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
ATE495247T1 (de) Chromoprotein und fluoroproteine
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2004044163A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2001072777A3 (en) Human transcription factors
DE60222422D1 (de) Mutationen in ionenkanälen
BRPI0309792A2 (pt) método para prevenção de incrustação em solução básica inibindo polimerização e solubilizando depósitos usando lactamas ou aminoácidos
WO2002095052A3 (en) Pna probes, probe sets, methods and kits pertaining to the detection of candida
WO2003063769A3 (en) Vesicle-associated proteins
WO2005124361A3 (en) Uses of gpr100 receptor in diabetes and obesity regulation
NO20081503L (no) T-celle adhesjonsmolekyl, og antistoff dertil
WO2001049714A3 (en) Nope polypeptides, encoding nucleic acids and methods of use
JPH10210974A5 (https=)
EP0911408A3 (en) DNA coding for serine/threonine kinase
WO2002081691A3 (en) Abcg5 and abcg8: compositions and methods of use
ATE462715T1 (de) Verfahren zur gezielten herstellung von lysobactinfragmenten
WO2002046378A3 (en) Alternative pol k nucleotide and amino acid sequence and methods for using